Company Projected Revenue: Capricor Therapeutics Inc. (CAPR)

The bet on long-term clinic demand for Duchenne muscular dystrophy therapy forms the financial basis of Capricor Therapeutics (CAPR). The company's sales target on GURU.Markets demonstrates a trend where the 0.00 mark records this indicator. Innovations in tissue regeneration offer hope to patients, yet the lack of stable cash flow and reliance on partner payments create operational inertia.

Company Expected Sales Volume: Capricor Therapeutics (CAPR) for 07/04/2022 - 11/15/2026

Summary analytical data breakdowns for Capricor Therapeutics (CAPR)

- stock value and consensus price forecast:

Price Chart Capricor Therapeutics|CAPR - Average Forecast Price

- company stock exchange capitalization indicators:

Market Value Capricor Therapeutics, Inc.|CAPR - Total Company Value

- balance sheet equity data:

Net Assets per Single Share Capricor Therapeutics|CAPR - Total Stockholders' Equity|Market Capitalization to Book Value Ratio capricor.com|CAPR - Company Balance Sheet Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

CAPR - Final Profit|Projected Future Earnings Capricor Therapeutics|CAPR - Business Payback Period|Forward P/E Multiple Capricor Therapeutics Inc.|CAPR - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Capricor Therapeutics Inc.|CAPR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Capricor Therapeutics|CAPR - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months capricor.com|CAPR - Earnings per share increase in current year|Expected earnings per share growth for next year Capricor Therapeutics

- sales and revenue data:

CAPR - Company Total Sales|Projected Sales Volume Capricor Therapeutics Inc.|CAPR - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Capricor Therapeutics Inc.|CAPR - Trailing Twelve Months Revenue Growth

Fundamental company analysis:Capricor Therapeutics Inc.

Investors value Capricor Therapeutics (CAPR) based on the commercialization potential of its R&D pipeline, where estimated revenue measures the recovery vector of operational activity based on projected cash flows from future sales. Analyzing the company's future sales model reveals the crossing of critical revenue thresholds, which is particularly significant as it prepares for the approval of deramiocele therapy and the drug's market entry.

Analysis of competing companies

Company Projected Revenue Jazz Pharmaceuticals Corp (JAZZ)|CYTK - Company Expected Sales Volume|Company Projected Revenue PTC Therapeutics Corp PTCT|Scholar Rock Inc. - Company Projected Revenue|CNTA - Company Projected Revenue|Company Sales Forecast Dyne Therapeutics (DYN)|EWTX: Projected Sales Volume|Company Sales Forecast Rapport Pharma RAPP|Company Future Sales Volume ALMS|Company Expected Sales Volume Zevra Therapeutics ZVRA|Projected Sales Volume CTNM|Company Projected Revenue LRMR (Larimar Therapeutics)|Company Projected Revenue Entrada TRDA|Company Future Revenue PTHS|MediciNova Inc. - Projected Sales Volume|Company Future Sales Serina Pharma SER|BTAI (BioXcel Therapeutics, Inc.) - Company Future Sales Volume|PMN - Company Future Sales|APUS (Apimeds Pharmaceuticals, Inc.) - Projected Sales Volume|AEON: Company Future Revenue|Projected Sales Volume NLSP|Company Future Sales Volume Bionomics BNOX|Projected Sales Volume HUGE (fsdpharma.com)|RETA (Reata Pharmaceuticals) - Company Expected Revenue